A lot of steam in the tank. GLp-1 class of drugs could see sales peak at $5.6 billon in a few years in China; around 600% increase from current market size.Demand already rocketed up along the first wave of off label use.
Like you said the drug is nothing new and obesity is not as endemic in China. So demand sored recently because it became popular in the U.S.